Synklino

Synklino

Live life again

Founded 2017 Denmark

Denmark 14 employees Series A Total: $232.00M Biotechnology, Health Care

Synklino is a biotechnology and health care startup, founded in 2017 and headquartered in Denmark. The company's slogan "Live life again" encapsulates its mission to provide rapid relief and improve long-term survival for transplant recipients by addressing cytomegalovirus (CMV) infections. Notably, CMV disease can lead to suboptimal transplantation outcomes, increased morbidity, prolonged hospitalization, and elevated mortality rates for transplant recipients. The company's drug candidate SYN002 is designed to efficiently eliminate both lytically and latently infected cells, effectively inhibiting viral replication and eradicating the virus from the transplant recipient's system. This approach aims to remove CMV as a complicating factor in transplantation. Moreover, SYN002 has shown high potency, efficiency, and selectivity in eliminating CMV-infected cells, making it suitable for standalone and combination therapy. Recently, on 08 June 2022, Synklino secured a significant kr222.00M Series A investment from a consortium of investors including Maj Invest Private Equity, Eir Ventures, Vaekstfonden, and PKA. This investment underscores the strong investor confidence in Synklino's innovative approach to combatting CMV infections and its potential to make a meaningful impact in the biotechnology and healthcare industries. As Synklino continues to advance its research and development efforts, the recent funding signals a promising trajectory for the company as it strives to deliver on its mission of providing life-saving solutions for transplant recipients.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	kr222.00M	4	Maj Invest Private Equity, Eir Ventures +2	08 Jun 2022
Seed Round	Undisclosed	2	Eir Ventures, Vaekstfonden	29 Sep 2020
Convertible Note	kr10.00M	1	BioInnovation Institute	01 Aug 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

kr222.00M

Maj Invest Private Equity, Eir Ventures +2

08 Jun 2022

Seed Round

Undisclosed

Eir Ventures, Vaekstfonden

29 Sep 2020

Convertible Note

kr10.00M

BioInnovation Institute

01 Aug 2019

FAQ About Synklino

Live life again

Synklino was founded in 2017.

Synklino is headquartered in Denmark.

Synklino operates in Biotechnology and Health Care. Its work centres on transplantation, immunotoxin, CMV infection and drug candidate.

Synklino has approximately 14 employees.

Synklino has completed 3 funding rounds, raising a total of $232.00M. The latest funding stage is Series A.

Top alternatives and competitors to Synklino include Apollo Therapeutics, Renibus Therapeutics Inc, Newron Pharmaceuticals SpA, Biohaven, Milestone Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Synklino and Apollo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Synklino

Funding Rounds & Investors (3)

Synklino Alternatives & Competitors

FAQ About Synklino